February 2, 2011

Sanofi-aventis Announces Positive Top-line Lixisenatide Phase III Results

 

Sanofi-aventis Announces Positive Top-line Lixisenatide Phase III Results

Paris, France – February 2, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that lixisenatide once-daily achieved primary efficacy endpoint and fewer hypoglycemias vs. exenatide twice-daily.